Viome Recognized by Frost & Sullivan as a 2019 Company of the Year for its Mission to Make Chronic Diseases Optional

NEXT STORY
Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic® in India
PREV STORY
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer

author_avatar
NASDAQ Market News

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

author_avatar
NASDAQ Market News

Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)

author_avatar
NASDAQ Market News